Pepgen Inc.
A clinical-stage biotech working to treat severe neuromuscular diseases, PepGen builds "oligonucleotide" medicines designed to fix faulty genetic instructions, using its EDO platform of cell-penetrating peptides to ferry drugs into muscle and other hard-to-reach tissues. Its lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 and has earned Orphan Drug and Fast Track designations. Founded in 2018, the company's name combines "Pep" for its peptide delivery technology and "Gen" for the genetic diseases it tackles.
Bought 200.0K
Bought 9.38M
Granted 187.7K · Sold 5.3K
Granted 76.8K · Sold 2.1K
Granted 50.3K · Sold 1.9K
Granted 65.7K
Granted 34.6K · Sold 1.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Oxford Science Enterprises plcFormer 10% Owner · 1 transaction | +4.2% | 4.96M | — | 200.0K | — |
| Kolchinsky Peter +4 co-filersDirector, 10% owner, Director · 1 transaction | — | 1.51M | — | 9.38M | — |
| McArthur James GPresident and CEO, Director · 3 transactions | +160.2% | 296.5K | 187.7K | — | 5.3K |
| Donnelly NoelChief Financial Officer · 3 transactions | +347.2% | 111.6K | 76.8K | — | 2.1K |
| Streck PaulEVP, Head of R&D · 3 transactions | +174.1% | 76.2K | 50.3K | — | 1.9K |
| Vittiglio JosephChief Business & Legal Officer · 2 transactions | — | 65.7K | 65.7K | — | — |
| Kasraian KasraChief Technical Officer · 2 transactions | +198.9% | 50.1K | 34.6K | — | 1.2K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +9.56M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.